AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat

AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat · Investor's Business Daily

In This Article:

AbbVie stock edged higher Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, Humira.